Explore the words cloud of the MaeBAia project. It provides you a very rough idea of what is the project "MaeBAia" about.
The following table provides information about the project.
Coordinator |
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 2˙499˙999 € |
EC max contribution | 2˙499˙999 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2017-ADG |
Funding Scheme | ERC-ADG |
Starting year | 2018 |
Duration (year-month-day) | from 2018-10-01 to 2023-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE | UK (LONDON) | coordinator | 2˙499˙999.00 |
Beta2 agonists (B2as) such as the short acting salbutamol, used to relieve acute wheeze, and the long acting salmeterol used to control asthma with inhaled steroids (ICS), are almost universally used in asthma. However, there is significant concern over morbidity and mortality related to adverse effects, particularly when used without ICS, and/or in excess at exacerbation (mostly caused by rhinovirus [RV] infection). The mechanisms of adverse effects are not understood. This proposal will rock the asthma world by revealing the mechanisms of these adverse effects, thus reducing asthma morbidity and mortality. I discovered that B2as induced, and augmented RV induction (to mimic exacerbation), of the pro-inflammatory mediator IL-6 in bronchial epithelial cells (BECs) in vitro, via a cAMP dependent mechanism. ICS suppressed this induction. Hundreds of asthma-related pro-inflammatory mediators and airway mucins have potential for induction by cAMP, and for suppression by ICS. I hypothesise that adverse effects of B2as are mediated by cAMP-dependent induction of pro-inflammatory mediators/mucins in BECs and macrophages and that ICS protect against induction. I will use RNA-seq to identify all mediators induced by B2as (±RV), and suppressed by ICS, in commercially sourced human BECs and macrophages (Mφ) and in primary BECs and Mφ from 8 mild asthmatics. I will develop qPCR/protein assays for these mediators, to confirm RNA-seq data, and identify mediators to study in vivo. I will study 24 mild asthmatics at baseline, after 14 days inhaled salmeterol and after 14 days inhaled salmeterol/ICS. To mimic B2a overuse at exacerbation, I will study 10 mild asthmatics to investigate the effect of high dose salbutamol. Clinical responses will be comprehensively assessed and airway inflammation will be studied using state of the art methods. It is essential that these studies are executed urgently to inform safest use of current asthma medication, and future drug development programs
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAEBAIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MAEBAIA" are provided by the European Opendata Portal: CORDIS opendata.